

1 **Title: Molecular profiling of primary renal diffuse large B-cell lymphoma unravels a**  
2 **proclivity for immune-privileged organ-tropism**

3

4 **Authors:** Axel Künstner<sup>1,2\*</sup>, Vera von Kopylow<sup>1,3,4\*</sup>, Philipp Lohneis<sup>4\*</sup>, Matthias  
5 Kümmel<sup>1,3,4</sup>, Hanno M. Witte<sup>1,3,5</sup>, Lorenz Bastian<sup>1,6</sup>, Veronica Bernard<sup>4</sup>, Stephanie Stölting<sup>4</sup>,  
6 Kathrin Kusch<sup>4</sup>, Manuela Krokowski<sup>4</sup>, Nikolas von Bubnoff<sup>1,3</sup>, Konrad Steinestel<sup>7</sup>, Annette  
7 Arndt<sup>7</sup>, Hartmut Merz<sup>4</sup>, Hauke Busch<sup>1,2\*\*</sup>, Alfred C. Feller<sup>4\*\*</sup>, Niklas Gebauer<sup>1,3\*\*</sup>

8

9 **Affiliations:**

10 <sup>1</sup> University Cancer Center Schleswig-Holstein, University Hospital of Schleswig-Holstein,  
11 Campus Lübeck, 23538 Lübeck, Germany

12 <sup>2</sup> Medical Systems Biology Group, University of Lübeck, Ratzeburger Allee 160, 23538  
13 Lübeck, Germany

14 <sup>3</sup> Department of Hematology and Oncology, University Hospital of Schleswig-Holstein,  
15 Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany

16 <sup>4</sup> Hämatopathologie Lübeck, Reference Centre for Lymph Node Pathology and  
17 Hematopathology, Maria-Goeppert-Straße 9a, 23562 Lübeck, Germany.

18 <sup>5</sup> Department of Hematology and Oncology, Federal Armed Forces Hospital Ulm, Oberer  
19 Eselsberg 40, 89081 Ulm

20 <sup>6</sup> Medical Department II, Hematology and Oncology, University Hospital Schleswig-Holstein,  
21 Kiel, Germany.

22 <sup>7</sup> Department of Pathology, Federal Armed Forces Hospital Ulm, Oberer Eselsberg 40, 89081  
23 Ulm

24

25

26

27 **Running Title:** Molecular landscape in primary renal DLBCL

28 **Key Words:** PR-DLBCL, molecular landscape, immune-privileged site, MHC Class I and II

29 **Word Count (Abstract): 200**

30 **Word Count (Text): 3.782**

31 **References: 57**

32 **Figures: 6**

33 **Supplementary Tables: 8**

34 **Supplemental Figures: 4**

35 **Supplementary References: 9**

36 **Competing Interests:** Niklas Gebauer received travel support from Beigene, Janssen, and  
37 Roche as well as honoraria from Roche, Takeda, Janssen, Menarini Stemline, and  
38 AstraZeneca.

39

40 \*These authors contributed equally to this manuscript.

41 \*\*Shared senior authorship

42 **Date of submission: 28.06.2024**

43

44 **Corresponding Author:**

45 PD Dr. med. Niklas Gebauer

46 Department of Hematology and Oncology

47 UKSH Campus Luebeck

48 Ratzenburger Allee 160

49 23538 Luebeck

50 Email: [Niklas.Gebauer@uksh.de](mailto:Niklas.Gebauer@uksh.de)

51

52 **Abstract:**

53 Primary renal manifestations of diffuse large B-cell lymphoma (PR-DLBCL) represent an  
54 exceptionally rare variant of the most common type of non-Hodgkin lymphoma (NHL).  
55 Insights into PR-DLBCL pathogenesis have been limited to small case series and  
56 methodologically limited approaches. The mechanisms driving lymphomagenesis within an  
57 organ lacking an intrinsic lymphatic niche and its proclivity for dissemination to immune-  
58 privileged sites, including testes and central nervous system, remain poorly understood. To  
59 decode the genetic and transcriptional framework of PR-DLBCL, we utilized whole exome  
60 sequencing, array-based somatic copy number alterations analysis, and RNA sequencing.  
61 Hereby we characterize the most extensive cohort of PR-DLBCL published, comprising 34  
62 samples from 30 patients. Despite significant mutational heterogeneity with a broad  
63 distribution among molecular clusters, we observed a strong unifying enrichment in  
64 deleterious MHC class I and II aberrations and loss of *CDKN2A* at a frequency similar to  
65 primary large B-cell lymphoma of immune privileged sites (IP-LBCL) alongside significant  
66 transcriptional deregulation of interferon signaling and *MYC* targets in MHC class I-deficient  
67 cases.

68 Our integrative assessment of PR-DLBCL biology expands the molecular understanding of  
69 this rare variant including similarities with IP-LBCL as an intriguing explanation for its  
70 clinical behavior and tropism. Our observations may inform future risk-adapted therapeutic  
71 approaches.

72

73 **Introduction:**

74 Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin  
75 lymphoma (NHL) and accounts for 30 – 40% of newly diagnosed lymphomas <sup>1</sup>. Extranodal  
76 manifestations in both the adrenal glands and the kidneys constitute long-standing risk factors  
77 for developing simultaneous or secondary CNS manifestations <sup>2</sup>. Secondary renal

78 involvement is recurrently observed in advanced-stage non-Hodgkin lymphoma (NHL),  
79 whereas primary renal (PR-) NHL manifestations are notably less frequent, leading to  
80 skepticism regarding the existence of primary renal lymphoma for an extended period <sup>2-6</sup>.  
81 Population-based datasets suggest an age-adjusted incidence of 0.035/100,000 with an  
82 increasing tendency, a median age of approximately 70 years at diagnosis, a male  
83 predominance, and mostly unilateral tumors. Among PR-NHL, DLBCL appears to be the  
84 most common histology followed by marginal zone (MZL) and follicular lymphoma (FL) <sup>7, 8</sup>.  
85 Clinical differentiation of PR-NHL from other renal malignancies including renal cell  
86 carcinoma poses a long-standing challenge, which led to a substantial number of PR-NHL  
87 patients undergoing curatively intended resection <sup>9</sup>. In recent years, the introduction of FDG-  
88 PET-CTs into routine clinical practice has enabled a more reliable characterization,  
89 particularly in patients with more aggressive PR-NHL <sup>10</sup>.  
90 Insufficient characterization of pathogenetic mechanisms in indolent PR-DLBCL derives  
91 from limited data, primarily comprised of small case series and a lack of in-depth molecular  
92 characterization of patients and samples <sup>11</sup>. Molecular drivers of lymphomas originating from  
93 organs lacking an intrinsic lymphatic niche, such as the kidney, remain widely elusive apart  
94 from individual case studies <sup>12</sup>. To elucidate the genetic and transcriptional landscape and  
95 drivers of PR-DLBCL, we conducted a comprehensive investigation employing whole exome  
96 sequencing (WES), array-based analysis of somatic copy number alterations (SCNA), and  
97 RNA sequencing (RNA-seq) to unravel both molecular properties of this rare entity as well as  
98 the cellular composition of its tumor microenvironment (TME).

99

## 100 **Materials and methods**

### 101 **Case selection and clinicopathological assessment**

102 For this retrospective analysis, we reviewed our institutional archive for cases of  
103 histologically confirmed primary renal DLBCL between January 2001 and December 2021.

104 Only such cases without concurrent non-renal lymphoma manifestations at diagnosis were  
105 included in the study, which led to a large subset of samples obtained by complete renal  
106 resection under the suspicion of non-metastatic renal cell carcinoma (22/34 samples; 65%).  
107 The study was approved by the ethics committee of the University of Lübeck (reference-no  
108 18-356) and conducted per the declaration of Helsinki. Patients provided written informed  
109 consent regarding routine diagnostic and academic assessment, including genomic studies.  
110 Histopathological work-up was performed as described and diagnosis was confirmed  
111 following the 5<sup>th</sup> edition WHO classification of hematopoietic and lymphoid tumors and the  
112 ICC criteria and yielded 34 cases of PR-DLBCL for which sufficient formalin-fixed paraffin-  
113 embedded (FFPE) tissue samples were available for subsequent molecular analysis <sup>1, 13, 14</sup>.

114

#### 115 **Delineation of the molecular composition of the study cohort**

116 Extraction of nucleic acids, WES and RNA-seq alongside detection of Somatic Copy Number  
117 Alterations employing the OncoScan CNV array (ThermoFisher was performed as described,  
118 and Raw fastq files have been added to the European Genome-phenome archive (EGA) under  
119 the previous accession number EGA50000000386 <sup>13, 15</sup>. OncoScan Array data has been  
120 deposited in Gene Expression Omnibus (GEO) under accession number GSE270422.

121

#### 122 **Whole exome data processing and variant calling**

123 The raw sequencing data in FASTQ format was processed using the NFORE workflow  
124 (NEXTFLOW v23.10.1) SAREK (v3.3.2) for variant calling against the GRCh38 reference  
125 genome <sup>16, 17</sup>. Initially, reads were trimmed for adapter sequences and quality using FASTP  
126 (v0.23.4), followed by alignment with BWA MEM2 (v2.2.1) <sup>18, 19</sup>. Subsequent steps included  
127 mate-pair information correction, removal of PCR duplicates, and base quality recalibration  
128 utilizing PICARD TOOLS, GATK (v4.4.0.0), and dbSNP v146 <sup>20, 21</sup>. Finally, variant calling was  
129 executed in tumor-only mode using MUTECT2 with GNOMAD (r2.1.1) as the reference for

130 known germline variants<sup>22, 23</sup>. Variants were left aligned (GATK  
131 LEFTALIGNANDTRIMVARIANTS) and only variants with a PASS filter flag were kept for  
132 variant annotation using VARIANT EFFECT PREDICTOR (VEP v111, GRCh38; adding CADD  
133 v1.6, dbNSFP v4.1a, and GNOMAD r3.0 as additional annotations)<sup>24-26</sup>. Next, annotations  
134 were converted into *MAF* format using *VCF2MAF* (V1.6.21)  
135 (DOI:10.5281/ZENODO.593251); coverage was extracted directly from the vcf INFO field.  
136 Potential FFPE artifacts in the variant data were identified using two approaches. First, strand  
137 orientation biases (mutations just found on one strand, F1R2 or F2R1) were detected by  
138 *SOBDETECTOR* (v1.0.4) and potential artifacts were removed<sup>27</sup>. Next, a classifier detecting  
139 the origin of mutation in formalin-fixation paraffin-embedding (FFPE) samples was applied  
140 (R-package *EXCERNO* v0.1.0)<sup>28</sup>. Variants annotated with an FFPE-like signature were  
141 removed. Potential germline variants in the data were removed using GATKs 1000g Panel of  
142 Normals. The top 20 frequently mutated genes (*FLAGS*)<sup>29</sup> were removed from further  
143 analysis and the remaining somatic variants were filtered as follows: minimum coverage of  
144 50, minimum alternative allele coverage of 5, minimum variant allele frequency of 10%, and  
145 only variants with a frequency < 0.1% in 1000 genomes, GNOMAD, or ExAC were  
146 considered for subsequent downstream analysis; variants were required to have a COSMIC or  
147 dbSNP ID. High-impact variants (CADD score > 20) in candidate genes (see below) were  
148 filtered as such that minimum coverage of 10, minimum alternative coverage of 4, and  
149 minimum variant allele frequency of 10% was required. Candidate genes were defined as  
150 follows: (a) listed as tumor suppressor or oncogene according to Vogelstein et al.<sup>30</sup>, (b) genes  
151 from the Lymphgen algorithm, (c) DLBCL genes described by Chapuy *et al.*, (d) MHC genes  
152 according to Harmonizome (v3.0)<sup>31-33</sup>. A brief graphical representation of the bioinformatics  
153 workflow for WES data processing is provided in **Supplementary Figure S1**.

154

## 155 **Detection of Somatic Copy Number Alterations**

156 Somatic copy number alterations were detected using OncoScan CNV assays (ThermoFisher).  
157 Raw data (CEL files) were processed using the EACON package (v0.3.6-2) with SEQUENZA  
158 as segmentation algorithm<sup>34</sup>. L2R files in CBS format were used as input for GISTIC  
159 (v2.0.22) to identify regions significantly amplified or deleted across all samples (confidence  
160 level 0.90, focal length cutoff 0.5, q-value threshold 0.1)<sup>34, 35</sup>.

161

162 For details on transcriptome data quantification, fusion detection, statistical analysis, and  
163 pseudonymization, please see **Supplementary Materials and Methods**.

164

## 165 **Results**

### 166 **Clinicopathological Characteristics and Cell-of-Origin in PR-DLBCL**

167 We collected 34 PR-DLBCL samples from 30 patients with sufficient FFPE tissue samples  
168 for in-depth molecular characterization (**Figure 1A**). The median age of the study group was  
169 66.5 years, 13 patients were female and 17 were male. No iatrogenic immunosuppression,  
170 immunodeficiency, and history or current presence of other lymphomas were reported in any  
171 of the patients. In particular, only patients without suspicion of concurrent lymphoma  
172 manifestations were eligible for the study. This is mirrored in the exceptionally high  
173 frequency of cases that underwent surgical resection of the kidney (22/34 cases; 65%).

174 Baseline clinicopathological data are summarized in **Supplementary Table 1**.

175 Structural variants in *BCL2*, *BCL6*, and *MYC* were assessed successfully in 19, 18, and 17  
176 patients by FISH break-apart probes. In cases without sufficient tissue for FISH but with  
177 RNA-seq data, we screened for high-confidence *BCL2/BCL6/MYC* fusions (**Figure 1 B**).

178 Here, we observed aberrations in five (26 %), two (11 %), and three (18%) cases respectively,  
179 indicative of a slightly elevated frequency of these aberrations in comparison to DLBCL  
180 (NOS) of other primary manifestations. In addition, we observed two cases with ETV6-Ig

181 fusions, previously described in PCNSL another case of an ETV6:PAX5 fusion respectively,  
182 previously described to lead to similar ETV6 activation in B-cell precursor acute  
183 lymphoblastic leukemia<sup>36, 37</sup>. Manually curated oncogenic fusions derived from RNA-seq  
184 data are summarized in **Supplementary Table 2**. By immunohistochemistry according to the  
185 Hans *et al.* algorithm in all samples with sufficient tissue available after DNA/RNA  
186 extraction, we observed the majority of cases to be of non-GCB type (18/30; 60%), whereas  
187 only a minor subset was of GCB type (11/30; 37%), and one case could not be classified due  
188 to insufficient immunoreactivity<sup>38</sup>. Only one case was EBV-associated (>50% positive tumor  
189 cells by EBER-ISH). To further unravel the cell of origin, we performed RNA-seq on samples  
190 from 30 patients and applied the approach proposed by Wright *et al.* and found 15/30 cases  
191 (50%) to be of ABC-subtype. In comparison, 9/30 (30%) were GCB-DLBCL and six  
192 remaining cases (20%) remained unclassifiable<sup>31, 39</sup> (**Figure 1 C**).

193

#### 194 **The mutational landscape of PR-DLBCL**

195 To elucidate the mutational landscape of PR-DLBCL and to screen for mutational drivers of  
196 the subgroup's peculiar tropism, we performed WES on FFPE tissue samples from 34 patients  
197 (**Figure 1 D**).

198 Adhering to stringent variant filtering, outlined above, oncogenic mutations were identified in  
199 all PR-DLBCL cases. In total 3,178 presumably deleterious mutations, affecting 1,388 genes  
200 were observed. Additionally, 25,457 somatic copy number aberrations (SCNAs) were  
201 detected. SNVs and indels comprised 11% of these mutations, of which 2,673 were missense  
202 (84%), 333 nonsense (10%) and 70 indel mutations (2%). Mutations affecting splice sites  
203 represented 3% of estimated somatic mutations and one of the observed mutations was a non-  
204 stop mutation (**Supplementary Table 3**). At an intermediate-low median tumor mutational  
205 burden (TMB) of 2.45 mutations/Mb (range 0.18 – 5.76), we observed no cases of  
206 microsatellite instability as could be expected in aggressive B-cell lymphomas. Variants per



207 variant class as well as variants per sample including information on variant subtypes are  
208 provided in **Supplementary Figure S2**.

209 The most commonly mutated genes included chromatin-remodeling genes *CREBBP* and  
210 *KMT2D* both in 56% of cases with > 20% nonsense mutations, followed by NOTCH  
211 signaling-associated genes *SPEN* and *NOTCH2* (both 50%) with nonsense mutations in 47%  
212 and 18% respectively. Overall, we observed an enrichment in IL6/JAK/STAT3 signaling  
213 mutations including *STAT3*, *PIMI*, and *MYD88*. While *STAT3* mutations were distributed  
214 throughout the entire gene, we observed mutational impairment of pre-described hotspots in  
215 *MYD88* and *PIMI* (all restricted to the kinase domain) (**Figure 2**). Other biological processes  
216 targeted by deleterious mutations in PR-DLBCL included the epigenetic regulation of gene  
217 expression (*SF3B1*, *KMT2D*, and *EZH2*), as well as B-cell receptor and RTK-RAS signaling  
218 (*CARD11*, *PRDMI*, and *BRAF*). The distribution of mutation onto the candidate driver genes  
219 referenced above is displayed in **Figure 2**. In a more global approach, we assessed the  
220 impairment of key biological processes through an enrichment analysis of mutations against  
221 previously described oncogenetic gene sets and against the IL6/JAK/STAT3 signaling  
222 pathway (**Figure 3**)<sup>40</sup>. Hereby we uncovered a relatively wide distribution within a given set  
223 (**Figure 3A**). Intriguingly, the most commonly affected gene sets included NOTCH, RTK-  
224 RAS, and IL6/JAK/STAT signaling at 97%, 94%, and 91%, respectively (**Figure 3 B, C**).  
225 Beyond this, we observed mutational impairment of PI3K signaling in 79% of cases,  
226 suggesting a significant role in PR-DLBCL pathogenesis. Correlating information on cell of  
227 origin and mutational patterns, we observed a statistically significant enrichment in mutations  
228 affecting *TNFAIP3* and *PIMI* among non-GCB cases. *BCL2* rearranged cases showed  
229 significantly more *DNMT1* and *SMARCA4* mutations (**Supplementary Figure S3**). We  
230 additionally screened for recurrent mutations in canonical tumor suppressor genes (TSGs) and  
231 found deleterious mutations in 33/34 (97%) cases. Among the most common targets, in  
232 addition to *CREBBP* and *KMT2D*, we observed mutations in *TP53* in 15% of cases.

233

## 234 **Genome-wide analysis of somatic copy-number variations in primary renal DLBCL**

235 To unravel the genome-wide landscape of SCNA in PR-DLBCL, we analyzed 29 samples  
236 successfully on the Illumina OncoScan array and subsequently employed GISTIC (v2.0.22) to  
237 identify regions significantly amplified or deleted across all samples. Arguably the most  
238 striking observation was a broad arm-level deletion spanning a large region on chromosome 6  
239 in 48% of evaluable cases (**Figure 4A**). Candidate genes, previously implicated in lymphoma  
240 pathogenesis located in this vast region included *PRDM1*, *NFKBIE*, *HLA-A*, *HLA-B*, and  
241 *ARID1B*. Beyond this aberration, the genome-wide CNV landscape of PR-DLBCL is  
242 dominated by CNVs affecting 3p12.1 and leading to copy number losses of *VHL*, *SETD2*,  
243 and others (17%), 9p21.3 encompassing the region encoding for TSG *CDKN2A* (38%), as  
244 well as the *NOTCH1* region at 9q34.3 (28%). Focal amplifications were observed at 1q23.1,  
245 3p12.3, 3q29, and 22q11.23. Candidate genes among significant deletions and amplifications  
246 are provided in **Supplementary Table 4** and **Figure 4B**. To assess the characteristics of PR-  
247 DLBCL in contrast to transcriptionally defined subtypes of DLBCL (ABC/GCB) and primary  
248 CNS lymphoma (PCNSL) as well as primary testicular large B-cell lymphoma (PTLBL)  
249 together representing the subgroup of primary large B-cell lymphomas of immune-privileged  
250 sites. We conducted a comparative analysis drawing CNV data from two previously published  
251 large-scale genome-wide studies (**Figure 4 C**)<sup>41, 42</sup>. Apart from a focal 3q29 amplification,  
252 none of the previously reported copy number gains were observed at a significant level in our  
253 cohort. At the same time and of particular interest, we observed strong similarities between  
254 PR-DLBCL, PCNSL, and PTLBL regarding deletions at 6p21.33, 6q21, and 6q23.3.  
255 Candidate gene deletions previously implicated in post-germinal differentiation and strong  
256 CNS tropism located at these loci include *HLA-B* and *PRDM1*. Moreover, we identified the  
257 above-mentioned *CDKN2A* deletions in PR-DLBCL at a frequency more similar to  
258 PCNSL/PTLBL than an all-comer DLBCL cohort. Additionally, we observed a significant

259 impact of SCNAs on gene-expression profiles which is shown exemplarily for TSGs  
260 (**Supplementary Figure S4**).

261

## 262 **Molecular clusters in primary renal DLBCL**

263 Building on our observations from WES, CNV analysis, RNA-seq, alongside structural  
264 variants identified by FISH for *BCL2*, *BCL6*, and *MYC*, we performed an integrative analysis  
265 on our entire cohort of PR-DLBCL samples to achieve an allocation to the previously defined  
266 molecular clusters (A53, N1, BN2, EZB, and MCD) based on the probabilistic LymphGen 2.0  
267 classifier<sup>31</sup>. Molecular data for an integrative analysis of sufficient sensitivity and specificity  
268 was available in 30 cases. Unlike previous observations in PCNSL/PTLBL, only one case  
269 resembled MCD-DLBCL. The most common molecular subtypes were ST2 (eight cases,  
270 27%) and EZB (five cases, 17%). Of note, no double- or triple-hit lymphomas including  
271 MYC+ EZB cases were observed. Only two cases were BN2-DLBCL (7%). While a  
272 significant overlap between signatures with compound-cluster allocation was observed in  
273 eight cases, six cases were found to exhibit a constellation of findings leading to a  
274 classification as “other” (**Figure 1 D** and **Supplementary Table 5**).

275

## 276 **Immune-escape mechanisms in primary renal DLBCL as a driver of tropism**

277 Following the characterization of the mutational profiles and molecular clusters that displayed  
278 the significant heterogeneity outlined above, we sought to understand the underlying  
279 mechanism behind the exceptional renal tropism in our present cohort. Building on our  
280 observation of a significant overlap between PR-DLBCL, PCNSL, and PTLBL, in particular  
281 regarding copy number losses affecting HLA-B as a hallmark gene of MHC Class I, we  
282 sought to assess the extent to which the clinical behavior of PR-DLBCL might be explained  
283 by immune escape strategies. Integrating all available datasets, we identified deleterious  
284 MHC Class I lesions in 72% of cases, including HLA-A and HLA-B deletions in 48% and

285 deleterious B2M mutations in 21% of evaluable patients (**Figure 5A, B**). An additional  
286 fraction of 33% of patients exhibited deleterious aberrations within the MHC class II  
287 machinery and 60% of patients additionally exhibited molecular hits in immediate interaction  
288 partners of MHC class I or II required for adequate immune response including del 19p13.3  
289 and mutations affecting CD70, CIITA, and CD58 (**Figure 5A, C**).

290 Having identified the large-scale 6p25.2-q27 deletion outlined above as a potential hallmark  
291 of aggressive B-cell lymphomas with renal tropism, we went on to assess the transcriptional  
292 profile of cases carrying said aberration and observed a significantly elevated expression of  
293 several candidate genes (**Figure 5D** and **Supplementary Table 6**) including *CXCL10* as well  
294 as strong enrichment for interferon alpha and gamma response, MYC targets, JAK/STAT  
295 signaling, and others (**Figure 5E** and **Supplementary Table 7**). In particular, we found  
296 downstream NFkB activation via TNFalpha signaling. In addition, several metabolic  
297 processes including glycolysis, fatty acid metabolism, and oxidative phosphorylation appear  
298 to be particularly engaged compared to non-MHC-class I-deleted cases.

299 Subsequent analysis of our cohort deconvoluting cell states and their assembly into  
300 communities of co-association patterns in the form of lymphoma ecotypes (LE) employing  
301 the lymphoma EcoTyper revealed a relatively diverse composition of both the tumor as well  
302 as its microenvironment in PR-DLBCL<sup>43</sup>. Despite the limited number of cases, we observed  
303 a trend towards enrichment in prognostically adverse ABC-DLBCL-associated lymphoma  
304 ecotypes (LE) 2 and 4 dominated by B-cells, plasma cells, and dendritic cells as well as NK  
305 cells, CD4 and CD8 positive T-cells alongside regulatory T-cells, respectively in del 6p25.2-  
306 q27 cases. Moreover, a trend towards enrichment of the T follicular helper cells dominated  
307 LE5 was observed in non-del 6p25.2-q27 cases<sup>43</sup>. The distribution of ecotypes on cases is  
308 depicted in **Figure 6 (Supplementary Table 8)**.

309

310 **Discussion**

311 Primary renal DLBCL poses a rare phenomenon associated with adverse clinical features and  
312 outcomes, including a so far unexplained CNS tropism leading to significant mortality,  
313 especially in relapsed and/or refractory cases <sup>6</sup>. This study was initiated to unravel the  
314 molecular underpinnings of primary renal disease, to allow for an understanding as to why  
315 and how the disease originates in an organ without a genuine lymphatic niche, and to explain  
316 the clinically observed tendency of early CNS progression. To this end, we conducted an  
317 integrative analysis employing WES, RNA-seq and array-based SCN analysis on the largest  
318 cohort of PR-DLBCL studied to date.

319 Hereby, we made the following noteworthy observations. First, we provide a detailed  
320 molecular landscape of PR-DLBCL and observe a strong degree of heterogeneity in terms of  
321 molecular clusters according to the LymphGen algorithm <sup>31</sup>. Contrary to our initial  
322 expectation, we observed a relatively low frequency of *MYD88* mutations. Therefore only one  
323 case that was allocated to the characteristic MCD cluster, which is otherwise recurrently  
324 observed in both primary and secondary CNS lymphoma as well as testicular lymphoma.  
325 Tropism for immune-privileged sites appears to be driven by immune escape strategies, which  
326 may be augmented by activating mutations in the B-cell receptor signaling cascade <sup>31, 32, 44, 45</sup>.  
327 Beyond this, we saw a high frequency of *SPEN* mutations previously described to be  
328 associated with early progression and inferior outcome in an all-comer DLBCL cohort <sup>46</sup>.  
329 Significant deregulation of TSGs was further validated via an integrative analysis of SCNAs  
330 and transcriptional abundance. Among the genes most commonly affected by mutations  
331 within our cohort, potentially targetable vulnerabilities included recurrent mutations in genes  
332 like *EZH2* for which clinically active inhibitors have been described previously, including  
333 combinations with *BCL2* inhibitors in patients with co-occurrence of *EZH2* and *BCL2*  
334 aberrations, which we observed in our cohort as well. At the same time, recurrent *CARD11*  
335 mutations, downstream of Bruton's tyrosine kinase (BTK) may render therapeutic  
336 approaches, employing BTK inhibitors inefficient in a clinically meaningful subset of patients

337 <sup>47-49</sup>. Given the peculiar tropism of PR-DLBCL, the abundance of *STAT3* mutations appears  
338 striking. In addition to the known cooperative interplay between *STAT3* and the NFκB  
339 signaling cascade in post-germinal DLBCL, this may further be explained as a selection  
340 advantage throughout clonal evolution. In keeping with previous observations that linked  
341 *STAT3* mutations and its elevated activity to the modulation of the abundance and function of  
342 regulatory T cells in the TME of solid cancers, this suggests a therapeutical perspective  
343 involving *STAT3* inhibition which might be able to target the TME and its permissive impact  
344 on the immunological niche in PR-DLBCL <sup>50, 51</sup>. An additional candidate driver for early  
345 progression and CNS dissemination is the relatively high rate of *MYC* aberrations in more  
346 than 17% of evaluable cases <sup>52</sup>.

347 Second, we describe a profile of SCNA and mutations leading to significant impairment of  
348 MHC class I/II families and its immediately associated genes in approx. 95% of cases in the  
349 cohort, which significantly exceeds observations in all-comer DLBCL cohorts <sup>32, 53</sup>. From  
350 these observations, we deduce a strong overlap between PR-DLBCL and large B-cell  
351 lymphomas of immune-privileged sites (IP-LBCL) regarding SCNAs. At the same time, PR-  
352 DLBCL apparently lacks the characteristic mutational profile resulting in tonic B-cell  
353 receptor signaling usually associated with this newly described entity <sup>1, 54</sup>. It is tempting to  
354 speculate on a theory of a first and second hit in the central nervous dissemination of PR-  
355 DLBCL acquiring the typical driver mutations in a second step, following the initial presence  
356 of strong immune-escape mechanisms <sup>55</sup>. To investigate this in future studies, paired analyses  
357 of renal and CNS tumors will be required. Deleterious aberrations in MHC class I  
358 components and related genes constitute well-documented phenomena in DLBCL. However,  
359 the frequency at which this is observed in the present study, extending to highly recurrent  
360 alterations of MHC class II genes poses a significant enrichment <sup>32</sup>. Moreover, this aligns  
361 with previous observations in primary CNS lymphoma and testicular lymphoma regarding  
362 deletions of the *HLA* and *CDKN2A* loci and extends well beyond previous reports in ABC-

363 DLBCL by both immunohistochemistry and gene expression profiling<sup>41</sup>. Further in keeping  
364 with pathogenetically similar trajectories between PR-DLBCL and other IP-LBCL, we  
365 observed 10% of cases harboring *ETV6* rearrangements previously reported as recurrent,  
366 oncogenic structural variants and drivers of a post-germinal phenotype in PCNSL<sup>36</sup>.

367 Third, we describe a characteristic transcriptional profile in cases harboring MHC class I  
368 SCNAs as a newly described hallmark of primary renal DLBCL. It is predominantly  
369 characterized by a strong enrichment for interferon alpha and gamma responses, MYC targets,  
370 and JAK/STAT signaling and downstream NFkB activation via TNF-alpha signaling. All of  
371 these mechanisms are known drivers, especially of ABC-DLBCL. TNF signaling was  
372 recently shown to aberrantly remodel the fibroblastic reticular cell (FRC) network and  
373 contribute to a tolerogenic TME hindering therapeutic efficacy of immune-based therapies<sup>51</sup>,  
374<sup>56</sup>. Further, several metabolic processes including glycolysis, fatty acid metabolism, and  
375 oxidative phosphorylation appear particularly engaged. This could be particularly interesting  
376 in future targeted therapeutical approaches exploiting this dependence, as recently described  
377<sup>57</sup>. In addition, we observed a trend towards enrichment of LE2- and LE4-high states in our  
378 predominantly ABC-like group of MHC class I deleted tumors, in keeping with previous  
379 observations from all-comer DLBCL cohorts where these lymphoma ecotypes were  
380 associated with inferior clinical outcomes<sup>43</sup>. The trend towards more LE5-high tumors in the  
381 non-MHC class I deleted cases with its underlying cell states being more prevalent in healthy  
382 lymphoid tissues integrates seamlessly with this notion.

383 The study presents several limitations, inherent to the retrospective design. Despite this being  
384 the largest cohort of PR-DLBCL to date the sample size remains limited and samples for the  
385 study were collected over more than two decades. This results in significant heterogeneity in  
386 terms of first- and later-line treatment approaches and limited follow-up information. These  
387 factors prohibit a meaningful integrative analysis of molecular findings and clinical  
388 endpoints. In addition, there is a potential for cases with occult non-renal primary

389 manifestations, which may have been missed by diagnosing physicians. However, considering  
390 that secondary renal manifestations typically occur in advanced-stage disease, the likelihood  
391 of a significant fraction of patients harboring secondary renal manifestations is relatively low.  
392 In summary, we present the largest molecular study on PR-DLBCL to date, untangle the  
393 genomic and transcriptional heterogeneity of the disease, and uncover evidence of significant  
394 pathogenetic overlap between PR-DLBCL and IP-LBCL. Our observations may inform future  
395 risk-adapted therapeutic approaches.

396

### 397 **Declarations**

### 398 **Ethics approval and consent to participate**

399 This retrospective study was approved by the ethics committee of the University of Lübeck  
400 (reference-no 18-356) and conducted in accordance with the declaration of Helsinki. Patients  
401 have provided written informed consent regarding routine diagnostic and academic  
402 assessment, including genomic studies of their biopsy specimens alongside the transfer of  
403 their clinical data.

404

405

### 406 **Availability of data and material**

407 Raw fastq files have been deposited in the European genome-phenome archive (EGA) under  
408 the accession number EGA50000000386. OncoScan Array data has been deposited in Gene  
409 Expression Omnibus (GEO) under accession number GSE270422.

410

### 411 **Funding**

412 This work was supported by generous funding by the Wilhelm Sander-Stiftung through a  
413 project grant (NG; Grant-Nr.: 2021.150.1). HB and AK acknowledge support from the BMBF  
414 project OUTLIVE-CRC (FKZ 01KD2103A).



415

416 **Author contributions**

417 Study concept: NG, ACF, HM

418 Data collection: NG, AK, VvK, PL, MK, HW, VB, SS, KK, HM, SS, KS, AA, ACF

419 Data analysis and creation of figures and tables: AK, NG, ACF, HB, NvB,

420 Initial Draft of manuscript: NG.

421 Critical revision and approval of final version: all authors.

422

423 **Acknowledgements**

424 The authors would like to thank Tanja Oeltermann for her skilled technical assistance. AK

425 and HB acknowledge computational support from the OMICS compute cluster at the

426 University of Lübeck.

427 **References**

- 428 1. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, *et al.*  
429 The 5th edition of the World Health Organization Classification of Haematolymphoid  
430 Tumours: Lymphoid Neoplasms. *Leukemia* 2022 Jul; **36**(7): 1720-1748.  
431
- 432 2. Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, *et al.* CNS  
433 International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse  
434 Large B-Cell Lymphoma Treated With R-CHOP. *J Clin Oncol* 2016 Sep 10; **34**(26): 3150-  
435 3156.  
436
- 437 3. Hu R, Zhang R, Miao M, Zhu K, Yang W, Liu Z. Central nervous system involvement  
438 of primary renal lymphoma with diffuse large B-cell type lymphoma. *Am J Case Rep* 2013;  
439 **14**: 292-294.  
440
- 441 4. Gibson TE. Lymphosarcoma of the kidney. *J Urol* 1948 Dec; **60**(6): 838-854.  
442
- 443 5. Kandel LB, McCullough DL, Harrison LH, Woodruff RD, Ahl ET, Jr., Munitz HA.  
444 Primary renal lymphoma. Does it exist? *Cancer* 1987 Aug 1; **60**(3): 386-391.  
445
- 446 6. Okuno SH, Hoyer JD, Ristow K, Witzig TE. Primary renal non-Hodgkin's lymphoma.  
447 An unusual extranodal site. *Cancer* 1995 May 1; **75**(9): 2258-2261.  
448
- 449 7. Taneja A, Kumar V, Chandra AB. Primary renal lymphoma: A population-based  
450 analysis using the SEER program (1973-2015). *Eur J Haematol* 2020 May; **104**(5): 390-399.  
451
- 452 8. Chen J, Peng J, Zheng Y, Li S, Yang P, Wu X, *et al.* Primary renal lymphoma: a  
453 population-based study in the United States, 1980-2013. *Sci Rep* 2019 Oct 22; **9**(1): 15125.  
454
- 455 9. Chen X, Hu D, Fang L, Chen Y, Che X, Tao J, *et al.* Primary renal lymphoma: A case  
456 report and literature review. *Oncol Lett* 2016 Nov; **12**(5): 4001-4008.  
457
- 458 10. Nicolau C, Sala E, Kumar A, Goldman DA, Schoder H, Hricak H, *et al.* Renal Masses  
459 Detected on FDG PET/CT in Patients With Lymphoma: Imaging Features Differentiating

- 460 Primary Renal Cell Carcinomas From Renal Lymphomatous Involvement. *AJR Am J*  
461 *Roentgenol* 2017 Apr; **208**(4): 849-853.  
462
- 463 11. Garcia M, Konoplev S, Morosan C, Abruzzo LV, Bueso-Ramos CE, Medeiros LJ.  
464 MALT lymphoma involving the kidney: a report of 10 cases and review of the literature. *Am*  
465 *J Clin Pathol* 2007 Sep; **128**(3): 464-473.  
466
- 467 12. Wen S, Liu T, Zhang H, Zhou X, Jin H, Sun M, *et al.* Whole-Exome Sequencing  
468 Reveals New Potential Mutations Genes for Primary Mucosa-Associated Lymphoid Tissue  
469 Lymphoma Arising From the Kidney. *Front Oncol* 2020; **10**: 609839.  
470
- 471 13. Künstner A, Schwarting J, Witte HM, Bernard V, Stölting S, Kusch K, *et al.*  
472 Integrative molecular profiling identifies two molecularly and clinically distinct subtypes of  
473 blastic plasmacytoid dendritic cell neoplasm. *Blood Cancer Journal* 2022 2022/07/04; **12**(7):  
474 101.  
475
- 476 14. Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, *et*  
477 *al.* The International Consensus Classification of Mature Lymphoid Neoplasms: a report from  
478 the Clinical Advisory Committee. *Blood* 2022 Sep 15; **140**(11): 1229-1253.  
479
- 480 15. Witte HM, Kunstner A, Hertel N, Bernd HW, Bernard V, Stolting S, *et al.* Integrative  
481 genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key  
482 regulatory pathways. *Blood Adv* 2021 Oct 29.  
483
- 484 16. Ewels PA, Peltzer A, Fillinger S, Patel H, Alneberg J, Wilm A, *et al.* The nf-core  
485 framework for community-curated bioinformatics pipelines. *Nat Biotechnol* 2020 Mar; **38**(3):  
486 276-278.  
487
- 488 17. Hanssen F, Garcia MU, Folkersen L, Pedersen AS, Lescai F, Jodoin S, *et al.* Scalable  
489 and efficient DNA sequencing analysis on different compute infrastructures aiding variant  
490 discovery. *NAR Genom Bioinform* 2024 Jun; **6**(2): lqae031.  
491
- 492 18. Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor.  
493 *Bioinformatics* 2018 Sep 1; **34**(17): i884-i890.

494

495 19. Vasimuddin M, Misra S, Li H, Aluru S. Efficient Architecture-Aware Acceleration of  
496 BWA-MEM for Multicore Systems. *2019 IEEE International Parallel and Distributed*  
497 *Processing Symposium (IPDPS) 2019*: 314-324.

498

499 20. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytzky A, *et al.* The  
500 Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA  
501 sequencing data. *Genome Res* 2010 Sep; **20**(9): 1297-1303.

502

503 21. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, *et al.* dbSNP:  
504 the NCBI database of genetic variation. *Nucleic Acids Res* 2001 Jan 1; **29**(1): 308-311.

505

506 22. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, *et al.*  
507 Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples.  
508 *Nat Biotechnol* 2013 Mar; **31**(3): 213-219.

509

510 23. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, *et al.* The  
511 mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* 2020  
512 May; **581**(7809): 434-443.

513

514 24. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, *et al.* The Ensembl  
515 Variant Effect Predictor. *Genome Biol* 2016 Jun 6; **17**(1): 122.

516

517 25. Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the  
518 deleteriousness of variants throughout the human genome. *Nucleic Acids Res* 2019 Jan 8;  
519 **47**(D1): D886-D894.

520

521 26. Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, *et al.* A genomic  
522 mutational constraint map using variation in 76,156 human genomes. *Nature* 2024 Jan;  
523 **625**(7993): 92-100.

524

525 27. Diossy M, Sztupinszki Z, Krzystanek M, Borcsok J, Eklund AC, Csabai I, *et al.* Strand  
526 Orientation Bias Detector to determine the probability of FFPE sequencing artifacts. *Brief*  
527 *Bioinform* 2021 Nov 5; **22**(6).

528

529 28. Mitchell A, Ruiz M, Yang S, Wang C, Davila JI. Excerno: Using Mutational  
530 Signatures in Sequencing Data to Filter False Variants Caused by Clinical Archival. *J Comput*  
531 *Biol* 2023 Apr; **30**(4): 366-375.

532

533 29. Shyr C, Tarailo-Graovac M, Gottlieb M, Lee JJ, van Karnebeek C, Wasserman WW.  
534 FLAGS, frequently mutated genes in public exomes. *BMC Med Genomics* 2014 Dec 3; **7**: 64.

535

536 30. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., Kinzler KW.  
537 Cancer genome landscapes. *Science* 2013 Mar 29; **339**(6127): 1546-1558.

538

539 31. Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, *et al.* A  
540 Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma  
541 with Therapeutic Implications. *Cancer Cell* 2020 Apr 13; **37**(4): 551-568 e514.

542

543 32. Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, *et al.* Molecular  
544 subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic  
545 mechanisms and outcomes. *Nat Med* 2018 May; **24**(5): 679-690.

546

547 33. Rouillard AD, Gundersen GW, Fernandez NF, Wang Z, Monteiro CD, McDermott  
548 MG, *et al.* The harmonizome: a collection of processed datasets gathered to serve and mine  
549 knowledge about genes and proteins. *Database (Oxford)* 2016; **2016**.

550

551 34. Favero F, Joshi T, Marquard AM, Birbak NJ, Krzystanek M, Li Q, *et al.* Sequenza:  
552 allele-specific copy number and mutation profiles from tumor sequencing data. *Ann Oncol*  
553 2015 Jan; **26**(1): 64-70.

554

555 35. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhi R, Getz G.  
556 GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-  
557 number alteration in human cancers. *Genome Biol* 2011; **12**(4): R41.

558

559 36. Bruno A, Labreche K, Daniau M, Boisselier B, Gauchotte G, Royer-Perron L, *et al.*  
560 Identification of novel recurrent ETV6-IgH fusions in primary central nervous system  
561 lymphoma. *Neuro Oncol* 2018 Jul 5; **20**(8): 1092-1100.

562

563 37. Smeenk L, Fischer M, Jurado S, Jaritz M, Azaryan A, Werner B, *et al.* Molecular role  
564 of the PAX5-ETV6 oncoprotein in promoting B-cell acute lymphoblastic leukemia. *EMBO J*  
565 2017 Mar 15; **36**(6): 718-735.

566

567 38. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, *et al.*  
568 Confirmation of the molecular classification of diffuse large B-cell lymphoma by  
569 immunohistochemistry using a tissue microarray. *Blood* 2004 Jan 1; **103**(1): 275-282.

570

571 39. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-  
572 based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.  
573 *Proc Natl Acad Sci U S A* 2003 Aug 19; **100**(17): 9991-9996.

574

575 40. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, *et al.* Oncogenic  
576 Signaling Pathways in The Cancer Genome Atlas. *Cell* 2018 Apr 5; **173**(2): 321-337 e310.

577

578 41. Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, *et al.* Targetable  
579 genetic features of primary testicular and primary central nervous system lymphomas. *Blood*  
580 2016 Feb 18; **127**(7): 869-881.

581

582 42. Monti S, Chapuy B, Takeyama K, Rodig SJ, Hao Y, Yeda KT, *et al.* Integrative  
583 analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle  
584 deregulation in diffuse large B cell lymphoma. *Cancer Cell* 2012 Sep 11; **22**(3): 359-372.

585

586 43. Steen CB, Luca BA, Esfahani MS, Azizi A, Sworder BJ, Nabet BY, *et al.* The  
587 landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. *Cancer Cell*  
588 2021 Oct 11; **39**(10): 1422-1437 e1410.

589

590 44. Wright GW, Wilson WH, Staudt LM. Genetics of Diffuse Large B-Cell Lymphoma. *N*  
591 *Engl J Med* 2018 Aug 2; **379**(5): 493-494.

592

593 45. Radke J, Ishaque N, Koll R, Gu Z, Schumann E, Sieverling L, *et al.* The genomic and  
594 transcriptional landscape of primary central nervous system lymphoma. *Nat Commun* 2022  
595 May 10; **13**(1): 2558.

596

597 46. Ren W, Wan H, Own SA, Berglund M, Wang X, Yang M, *et al.* Genetic and  
598 transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within  
599 two years of diagnosis. *Leukemia* 2024 Mar; **38**(3): 610-620.

600

601 47. Caeser R, Walker I, Gao J, Shah N, Rasso-Barnett L, Anand S, *et al.* Acquired  
602 CARD11 mutation promotes BCR independence in Diffuse Large B Cell Lymphoma. *JCO*  
603 *Precis Oncol* 2021; **5**: 145-152.

604

605 48. Scholze H, Stephenson RE, Reynolds R, Shah S, Puri R, Butler SD, *et al.* Combined  
606 EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes.  
607 *Blood Adv* 2020 Oct 27; **4**(20): 5226-5231.

608

609 49. Morschhauser F, Salles G, Batlevi CL, Tilly H, Chaidos A, Phillips T, *et al.* Taking  
610 the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas. *Blood Rev* 2022  
611 Nov; **56**: 100988.

612

613 50. Oweida AJ, Darragh L, Phan A, Binder D, Bhatia S, Mueller A, *et al.* STAT3  
614 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck  
615 Cancer. *J Natl Cancer Inst* 2019 Dec 1; **111**(12): 1339-1349.

616

617 51. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, *et al.* Cooperative  
618 signaling through the signal transducer and activator of transcription 3 and nuclear factor-  
619 kappaB pathways in subtypes of diffuse large B-cell lymphoma. *Blood* 2008 Apr 1; **111**(7):  
620 3701-3713.

621

622 52. Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, *et al.*  
623 Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large  
624 B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. *J Clin*  
625 *Oncol* 2019 Dec 10; **37**(35): 3359-3368.

626

627 53. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, *et al.*  
628 Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. *N Engl J Med* 2018 Apr 12;  
629 **378**(15): 1396-1407.

630

631 54. Roschewski M, Phelan JD, Jaffe ES. Primary Large B-cell Lymphomas of Immune-  
632 Privileged Sites. *Blood* 2024 Apr 18.

633

634 55. Watanabe J, Natsumeda M, Okada M, Kobayashi D, Kanemaru Y, Tsukamoto Y, *et*  
635 *al.* High Detection Rate of MYD88 Mutations in Cerebrospinal Fluid From Patients With  
636 CNS Lymphomas. *JCO Precis Oncol* 2019 Dec; **3**: 1-13.

637

638 56. Apollonio B, Spada F, Petrov N, Cozzetto D, Papazoglou D, Jarvis P, *et al.* Tumor-  
639 activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma. *J*  
640 *Clin Invest* 2023 Jul 3; **133**(13).

641

642 57. Noble RA, Thomas H, Zhao Y, Herendi L, Howarth R, Dragoni I, *et al.* Simultaneous  
643 targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse  
644 large B-cell lymphoma. *Br J Cancer* 2022 Sep; **127**(5): 937-947.

645

646

647



648 **Figure Legends:**

649

650 **Figure 1. Molecular landscape of PR- DLBCL.** A Venn diagram depicting the number of samples  
651 for which WES (n = 34), RNA-seq (n = 30), and OncoScan arrays (n = 29) were successfully  
652 conducted. **B** Fusion identified by RNA-sequencing in PR-DLBCL samples (beyond  
653 *MYC/BCL2/BCL6* rearrangements identified in cases studied by FISH) displayed by their genomic  
654 location. **C** Sankey plot illustrating the distribution of cases of PR-DLBCL into the categories  
655 GCB/non-GCB by immunohistochemistry (IHC) according to the algorithm proposed by Hans *et al.*<sup>38</sup>  
656 as well as by Cell-of-origin (CoO) classified according to gene-expression profiling<sup>39</sup> derived from  
657 RNA-seq and lastly according to molecular clusters drawn from the LymphGen algorithm, integrating  
658 data from WES, RNA-seq, Oncoscans, and FISH (*BCL2/BCL6/MYC*)<sup>31</sup>, depicting the significant  
659 degree of molecular heterogeneity. **D** Oncoplot displaying putative driver genes and the number of  
660 samples harboring mutations in a given gene (right bar). Mutation types are color-coded, and  
661 covariates, including sex, CoO, FISH results for *BCL2/BCL6/MYC*, and type of biopsy (punch/needle  
662 core vs. open resection/nephrectomy) are shown below for each sample.

663

664 **Figure 2. Recurrently mutated putative drivers of PR-DLBCL.** Lollipop plots illustrating types  
665 and location of mutations, grouped by affected signaling pathway and/or biological function.  
666 Functional domains are depicted as a frame of reference and the lollipops' height indicates the  
667 frequency with which a given mutation occurred in our cohort.

668

669 **Figure 3. Functional implication of mutations in PR-DLBCL.** A Fraction of a given pathway,  
670 biological function, or gene set impaired by mutations is depicted as the number of affected genes vs.  
671 the number of genes in a given set. **B** Distribution of mutational impairment of gene sets per sample,  
672 including fraction of samples harboring one or more mutations in a given gene set.

673

674 **Figure 4. Somatic copy-number aberrations in PR-DLBCL compared with other subtypes of**  
675 **DLBCL including IP-LBCL.** A Location of SCNAs along the genome and GISTIC G-scores (G =

676 Frequency  $\times$  Amplitude; red bars denote gains and blue bars losses; gene names refer to affected  
677 oncogenes and tumor suppressor genes within identified regions). **B** Tumor suppressor genes affected  
678 by copy number losses. **C** Amplifications and deletions at recurrently affected loci in an all-comer  
679 cohort of DLBCL (first column), DLBCL of ABC- as well as GCB-subtype (second and third column)  
680 and IP-LBCL with primary CNS or primary testicular manifestation (column four and five) compared  
681 to primary renal DLBCL (column six).





682

683 **Figure 5. Immune escape is the predominant molecular feature of PR-DLBCL. A** Impairment of  
684 the MHC class I and II apparatus as well as its immediate interaction partners by mutations and/or  
685 SCNAs. **B, C** Lollipop plots illustrating types and location of mutations in *B2M* and *CIITA* as  
686 recurrently mutated genes associated with immune escape in PR-DLBCL. Functional domains are  
687 depicted as a frame of reference and the lollipops' height indicates the frequency with which a given  
688 mutation occurred in our cohort. **D** Volcano plot illustrating results of a genome-wide screen for  
689 significantly deregulated genes by the presence or absence of a large-scale deletion on chromosome 6  
690 leading to strong MHC class I impairment as the most recurrent and striking feature in PR-DLBCL.  
691 **E** Gene-set enrichment analysis depicting functional implications of deregulated gene expression  
692 between cases with and without large-scale MHC class I deletions.




693

694 **Figure 6. Deconvolution of PR- DLBCL transcriptomes employing the lymphoma EcoTyper. A**  
695 Heatmap displaying the cell-type abundance as well as the predominant EcoType for a given PR-  
696 DLBCL sample. **B** Comparative analysis of lymphoma EcoType abundances according to the  
697 presence or absence of a large-scale deletion on chromosome 6 leading to strong MHC class I  
698 impairment as the most recurrent and striking feature in prDLBC, grouped by lymphoma EcoTypes.




699






## A NOTCH Signaling




## C Epigenetic regulation of gene expression




## B IL6/JAK/STAT3 Signaling




## D Signaling by the B-Cell Receptor BCR



## E KRAS Signaling Up








## F RTK-RAS







### Variant Classification

- Missense Mutation
- Nonsense Mutation
- Splice Site

**A****B**





**A**

## PR-DLBCL data assigned to Lymphoma Ecotypes

**B**